No profile data available.
NRx Pharmaceuticals, Inc. (NRXP) is a healthcare company in the brain and nerve treatment drugs industry, based in Wilmington, United States, with about 29 full-time employees.
It reported revenue of $1.23 million for fiscal year 2025, and net income of -$28.62 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $1.10 million. Its market capitalization was $123.39 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.
NRx Pharmaceuticals reported $1.23 million in revenue for fiscal year 2025. In Q2 2026 revenue was $1.10 million.
$123.39 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Voyager Therapeutics, Inc. (VYGR), Anavex Life Sciences Corp. (AVXL), Tonix Pharmaceuticals Holding Corp. (TNXP), Coya Therapeutics, Inc. (COYA).